Skip to main content

Table 1 TA concentration in vials over time

From: Therapeutic and pharmaco-biological, dose-ranging multicentre trial to determine the optimal dose of TRAnexamic acid to reduce blood loss in haemorrhagic CESarean delivery (TRACES): study protocol for a randomised, double-blind, placebo-controlled trial

Concentration of TA (mg/mL) Day 0 Day 15 Day 30 Day 60 Day 90 6 months 9 months 1 year
Vials with TA 0.5 g/10 mL 46
[45–47]
45,67
[44–49]
50.33
[49–52]
51
[50–52]
47.33
[46–50]
57.33
[54–61]
54.66
[53–56]
51
[50–52]
Vials with TA 1 g/10 mL 96
[93–101]
103.67
[102–109]
106
[102–112]
102.33
[102–103]
97
[96–98]
109.75
[106–114]
101.33
[101–102]
99.33
[99–100]
  1. TA tranexamic acid